AbbVie Inc.ABBV

時価総額

$4173.7億

PER

研究開発型医薬品の米国最大手。免疫学、腫瘍、神経科向けの革新的治療薬を展開。2024年12月にAliadaを約14億ドルで買収、同年6月にCelsiusを2.5億ドルで買収。米国中心に世界展開、海外売上比率は約24%（2024年）。

	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net earnings	-	-	-	-	-	-	-	4,622	11,549	11,845	4,873	4,286
Depreciation	388	383	417	425	425	471	464	666	803	778	752	764
Amortization of intangible assets	509	403	419	764	1,100	1,300	1,600	5,800	7,700	7,700	7,900	7,600
Deferred income taxes	-	-	-	-	-	-	122	-2,325	-898	-1,931	-2,889	-1,449
Change in fair value of contingent consideration liabilities	-	-	-	228	626	49	3,091	5,753	2,679	2,761	5,128	3,771
Payments of contingent consideration liabilities	-	-	-	-	-	-	-	-	-	-	870	1,995
Stock-based compensation	212	241	282	353	365	421	430	753	692	671	747	911
Acquired IPR&D and milestones	-	1,102	280	280	470	1,061	490	1,376	1,624	697	778	2,757
Gain on divestitures	-	-	-	-	-	-	330	-	68	172	-	-
Non-cash litigation reserve adjustments, net of cash payments	-	-	-	-	-	-	-	-	-	2,243	-443	508
Impairment of intangible assets	-	-	-	-	354	5,070	1,030	-	-	770	4,229	4,476
Other, net	-34	-434	-489	-429	-84	-76	-43	-832	-	150	225	63
Accounts receivable	-	-	-	71	391	591	74	929	1,321	1,455	-66	-207
Inventories	56	203	434	38	-93	226	231	40	142	686	417	319
Prepaid expenses and other assets	-459	220	-511	393	118	499	-97	-134	197	264	188	-361
Accounts payable and other liabilities	-426	-193	1,503	-1,187	425	190	-1,121	1,514	1,628	1,605	3,840	177
Income tax assets and liabilities, net	-	-	-	-	-	-	-	-573	-1,290	542	-488	-3,208
Cash flows from operating activities	-	-	-	-	-	-	13,324	17,588	22,777	24,943	22,839	18,806
Acquisition of businesses, net of cash acquired	405	622	11,488	2,495	-	-	-	38,260	525	255	-	17,493
Other acquisitions and investments	-	-	964	262	308	736	1,135	1,400	1,400	539	1,200	3,000
Acquisitions of property and equipment	491	612	532	479	529	638	552	798	787	695	777	974
Purchases of investment securities	930	1,169	851	5,315	2,230	1,792	583	61	119	1,438	77	73
Sales and maturities of investment securities	2,705	1,477	880	2,359	2,793	2,160	2,699	1,525	98	1,530	55	555
Other, net	-	-	-19	-118	-	-	-167	-1,387	-366	-774	-13	-189
Cash flows from investing activities	-	-	-	-	-	-	596	-37,557	-2,344	-623	-2,009	-20,820
Proceeds from Short-Term Debt	-	-	-	-	-	-	-	-	-	-	-	5,008
Repayments of Other Short-Term Debt	-	-	-	-	-	-	3,000	-	-	-	-	5,008
Proceeds from issuance of long-term debt	-	-	20,660	11,627	-	5,963	31,482	3,000	1,000	2,000	-	16,963
Repayments of long-term debt and finance lease obligations	-	-	4,018	6,010	25	6,035	1,536	5,683	9,414	14,433	4,149	9,613
Debt issuance costs	-	-	182	69	-	40	424	20	-	-	38	99
Dividends paid	2,555	2,661	3,294	3,717	4,107	5,580	6,366	7,716	9,261	10,043	10,539	11,025
Purchases of treasury stock	320	652	7,567	6,033	1,410	12,014	629	978	934	1,487	1,972	1,708
Proceeds from Stock Options Exercised	347	225	142	268	254	73	8	209	244	262	180	214
Payments of contingent consideration liabilities	-	-	-	-	268	78	163	321	698	1,132	752	-
Other, net	-66	-217	30	35	22	14	35	8	24	30	48	57
Cash flows from financing activities	-	-	-	-	-	-14,396	18,708	-11,501	-19,039	-24,803	-17,222	-5,211
Effect of exchange rate changes on cash and equivalents	-	-	-	-	-	-	-	-	-	-62	5	-65
Net change in cash and equivalents	-	-	-	-	-	-	-	-31,475	1,297	-545	3,613	-7,290
Interest paid, net of portion capitalized	283	419	536	986	1,099	1,215	1,794	2,619	2,712	2,546	2,469	2,811
Income taxes paid	1,305	498	1,108	3,563	1,696	-	1,447	1,674	3,648	2,988	4,702	4,064